L'intérêt à découvert pour CG Oncology donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de CG Oncology. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

CG Oncology (NASDAQ:CGON) Stock, Rapport sur les intérêts à découvert

CG Oncology

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

CG Oncology Inc

Stride (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LRN#NYSE">LRN</a>) has outperformed the market over the past 10 years by 15.12% on an annualized basis producing an average annual return of 25.31%. Currently, Stride has a market capitalization of $6.13 billion. 
Buying $1000 In LRN: If an investor had bought $1000 of LRN stock 10 years ago, it would be worth $8,803.75 today based on a price of $140.86 for LRN at the time of writing.
<h3>Stride's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745878510_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

Here's How Much You Would Have Made Owning Stride Stock In The Last 10 Years

GITS

Global Interactive Technologies Receives Delinquency Compliance Alert Notice from Nasdaq

General

Delek Logistics Partners Increases Quarterly Cash Distribution To $1.11 Per Common Limited Partner Unit

In October 2021, <a href="https://www.benzinga.com/general/education/25/04/44992374/elon-musk-is-122-billion-poorer-in-2025-and-still-richer-than-bezos-huang-cuban-combined">Elon Musk had just been crowned</a> the richest person on Earth. David Beasley, head of the United Nations World Food Program at the time, didn't miss a beat. In a tweet tagging Musk, he wrote:
"Congratulations to @elonmusk for passing up @JeffBezos as the world's richest person — worth a whopping $221B! Elon, to celebrate I'm offering you a once in a lifetime opportunity: help us save 42M people from starvation for just $6.6B!!"
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>
It was a direct challenge — not a polite ask. And it came days before Beasley <a href="https://www.cnn.com/2021/10/26/economy/musk-world-hunger-wfp-intl/index.html">appeared on CNN on Oct. 26,2021</a> , warning that "$6 billion to help 42 million people that are literally going to die if we don't reach them" wasn't a theory, it was a matter of survival. "It's not complicated," he told Connect the World. Governments were "tapped out," he said, and it was time for billionaires to step up — "on a one-time basis."
Besley went on to point out how Musk added $6 billion to his net worth in a single day. This was a mere fraction of his wealth. He asked, "what if it was your daughter starving to death? What if it was your family starving to death?" He pleaded, "Wake up, smell the coffee and help."
Five days later, Musk responded, saying: "If WFP can describe on this Twitter thread exactly how $6B will solve world hunger, I will sell Tesla stock right now and do it." He followed it with a condition: "But it must be open source accounting, so the public sees precisely how the money is spent."<a href="https://twitter.com/elonmusk/status/1454808104256737289">&nbsp;</a>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">If WFP can describe on this Twitter thread exactly how $6B will solve world hunger, I will sell Tesla stock right now and do it.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1454808104256737289?ref_src=twsrc%5Etfw">October 31, 2021</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Trending: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
Beasley replied that $6 billion wouldn't end world hunger — but it could save millions from starvation. "This is a one-time donation to save 42 million lives during this unprecedented hunger crisis," he said. "The world is on fire."
On Nov. 15, 2021 the WFP <a href="https://x.com/WFPChief/status/1460323875804397568">published a spending plan</a> showing how $6.6 billion would be used to provide food assistance to 42 million people in 43 countries. The plan included $3.5 billion for food procurement and delivery, $2 billion for cash and food vouchers, $700 million to develop country-specific programs, and $400 million for administration, oversight, and logistics. Beasley tweeted the link directly to Musk, adding, "You asked for a clear plan &amp; open books. Here it is!"
Despite the detailed plan the WFP released, Musk never publicly replied or engaged further. It's worth noting: the response didn't occur within the same Twitter thread — a specific condition Musk outlined in his original challenge.&nbsp;
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
When the UN released its plan, reactions online were mixed. While some praised the transparency, others argued it fell short of Musk's challenge. Supporters pointed out that the plan outlined how to prevent famine, not how to end world hunger entirely — a key distinction. Some critics said the proposal was too focused on short-term relief and logistics, rather than offering a sustainable, long-term solution. Others questioned the large administrative and operational costs included in the budget.
Weeks later, an <a href="https://www.sec.gov/Archives/edgar/data/1318605/000089924322006240/xslF345X03/doc5.xml">SEC filing</a> revealed that Musk had donated roughly $5.7 billion worth of Tesla stock to charity in November 2021. The recipient was not disclosed at the time, leading to speculation about whether the WFP ever received the funds.
By early 2022, <a href="https://www.bloomberg.com/news/articles/2022-12-12/elon-musk-s-5-7-billion-mystery-gift-went-to-his-own-charity">Bloomberg reported</a> the donation went to <a href="https://www.benzinga.com/tech/25/01/42781835/elon-musk-donates-tesla-shares-worth-over-101-million-to-charity">Musk's own philanthropic organization</a>, the Musk Foundation — not the WFP. According to <a href="https://philanthropynewsdigest.org/news/other-sources/article/?id=11889652&amp;title=Elon-Musk%E2%80%99s-Mystery-$5.7-Billion-Donation-Revealed-To-Be-To-His-Own-Charity">Philanthropy News Digest</a>, the Musk Foundation later distributed $160 million in 2021, with the largest portions going to St. Jude Children's Research Hospital at $55 million and the XPrize Foundation with $54 million.&nbsp;
Hunger continues to affect about 733 million people globally, or roughly one in 11 people, according to the latest <a href="https://www.who.int/publications/m/item/the-state-of-food-security-and-nutrition-in-the-world-2024">State of Food Security and Nutrition report</a> by the World Health Organization. <a href="https://www.fao.org/documents/card/en/c/CC7724EN">&nbsp;</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>
Image: Shutterstock

Personal Finance

Elon Musk Said He'd Give $6 Billion to End World Hunger If the UN Could Explain How — They Did, But He Didn't Give Them a Dime

In the last three months, 9 analysts have published ratings on SiteOne Landscape Supply (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SITE#NYSE">SITE</a>), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $141.11, a high estimate of $182.00, and a low estimate of $106.00. Experiencing a 5.69% decline, the current average is now lower than the previous average price target of $149.62. 
<img src="https://www.benzinga.com/files/images/story/2025/1745877677_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of SiteOne Landscape Supply among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;W. Andrew Carter &#x7C;Stifel &#x7C;Lowers &#x7C;Hold &#x7C; $126.00&#x7C;$145.00 &#x7C; 
&#x7C;Matthew Bouley &#x7C;Barclays &#x7C;Lowers &#x7C;Underweight &#x7C; $106.00&#x7C;$120.00 &#x7C; 
&#x7C;Jeffrey Stevenson &#x7C;Loop Capital &#x7C;Lowers &#x7C;Hold &#x7C; $125.00&#x7C;$150.00 &#x7C; 
&#x7C;Collin Verron &#x7C;Deutsche Bank &#x7C;Announces &#x7C;Hold &#x7C; $135.00&#x7C;- &#x7C; 
&#x7C;W. Andrew Carter &#x7C;Stifel &#x7C;Raises &#x7C;Hold &#x7C; $145.00&#x7C;$140.00 &#x7C; 
&#x7C;Mike Dahl &#x7C;RBC Capital &#x7C;Raises &#x7C;Sector Perform &#x7C; $136.00&#x7C;$129.00 &#x7C; 
&#x7C;Damian Karas &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $182.00&#x7C;$185.00 &#x7C; 
&#x7C;David Manthey &#x7C;Baird &#x7C;Lowers &#x7C;Outperform &#x7C; $175.00&#x7C;$183.00 &#x7C; 
&#x7C;W. Andrew Carter &#x7C;Stifel &#x7C;Lowers &#x7C;Hold &#x7C; $140.00&#x7C;$145.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to SiteOne Landscape Supply. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of SiteOne Landscape Supply compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of SiteOne Landscape Supply's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into SiteOne Landscape Supply's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SITE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on SiteOne Landscape Supply analyst ratings.</a>
<h2>Delving into SiteOne Landscape Supply's Background</h2>
SiteOne Landscape Supply Inc is a supplier of tools and equipment. The company serves various businesses which include wholesale irrigation, outdoor lighting, nursery, landscape supplies, grass seeds, and fertilizers, turf protection products, turf care equipment, and golf course accessories for green industry professionals mainly in the United States and Canada. Its product portfolio includes irrigation supplies, fertilizer and herbicides, landscape accessories, nursery goods, natural stones and blocks, outdoor lighting and ice melt products and other products.
<h3>SiteOne Landscape Supply: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: SiteOne Landscape Supply displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 4.98%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: SiteOne Landscape Supply's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -2.14%, the company may face hurdles in effective cost management.
Return on Equity (ROE): SiteOne Landscape Supply's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -1.36%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.7%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: SiteOne Landscape Supply's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.6.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

SITE

A Glimpse Into The Expert Outlook On SiteOne Landscape Supply Through 9 Analysts

In the preceding three months, 16 analysts have released ratings for PVH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $95.19, along with a high estimate of $160.00 and a low estimate of $68.00. This current average has decreased by 16.46% from the previous average price target of $113.94. 
<img src="https://www.benzinga.com/files/images/story/2025/1745877665_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of PVH by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;---------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Adrienne Yih &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $87.00&#x7C;$103.00 &#x7C; 
&#x7C;Matthew Boss &#x7C;JP Morgan &#x7C;Lowers &#x7C;Neutral &#x7C; $87.00&#x7C;$91.00 &#x7C; 
&#x7C;Paul Lejuez &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $68.00&#x7C;$83.00 &#x7C; 
&#x7C;Adrienne Yih &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $103.00&#x7C;$98.00 &#x7C; 
&#x7C;Kimberly Greenberger&#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $86.00&#x7C;$95.00 &#x7C; 
&#x7C;Ashley Helgans &#x7C;Jefferies &#x7C;Lowers &#x7C;Hold &#x7C; $80.00&#x7C;$101.00 &#x7C; 
&#x7C;Dana Telsey &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Outperform &#x7C; $90.00&#x7C;$90.00 &#x7C; 
&#x7C;Simeon Siegel &#x7C;BMO Capital &#x7C;Lowers &#x7C;Market Perform &#x7C; $93.00&#x7C;$106.00 &#x7C; 
&#x7C;Michael Binetti &#x7C;Evercore ISI Group &#x7C;Lowers &#x7C;Outperform &#x7C; $105.00&#x7C;$139.00 &#x7C; 
&#x7C;Dana Telsey &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Outperform &#x7C; $90.00&#x7C;$90.00 &#x7C; 
&#x7C;Paul Lejuez &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $72.00&#x7C;$123.00 &#x7C; 
&#x7C;Dana Telsey &#x7C;Telsey Advisory Group&#x7C;Lowers &#x7C;Outperform &#x7C; $90.00&#x7C;$130.00 &#x7C; 
&#x7C;Jay Sole &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $160.00&#x7C;$172.00 &#x7C; 
&#x7C;Brooke Roach &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $109.00&#x7C;$128.00 &#x7C; 
&#x7C;Adrienne Yih &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $98.00&#x7C;$144.00 &#x7C; 
&#x7C;Ike Boruchow &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $105.00&#x7C;$130.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to PVH. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of PVH compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of PVH's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of PVH's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PVH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on PVH analyst ratings.</a>
<h2>Discovering PVH: A Closer Look</h2>
PVH designs and markets branded apparel in more than 40 countries. Its key fashion categories include men's dress shirts, ties, sportswear, underwear, and jeans. Its two designer brands, Calvin Klein and Tommy Hilfiger, now generate practically all its revenue after its recent disposition of most of its smaller brands. PVH operates e-commerce sites, about 1,400 stores, and about 1,500 shop-in-shops and concessions. The firm also licenses its brands to third parties and distributes its merchandise through department stores and other wholesale accounts. PVH traces its history to 1881 and is based in New York City.
<h3>PVH: Financial Performance Dissected</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining PVH's financials over 3M reveals challenges. As of 31 January, 2025, the company experienced a decline of approximately -4.75% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: PVH's net margin is impressive, surpassing industry averages. With a net margin of 6.63%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): PVH's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.01% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.41%, the company showcases effective utilization of assets.
Debt Management: PVH's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.66.
<h2>What Are Analyst Ratings?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On PVH Through 16 Analysts

In the preceding three months, 5 analysts have released ratings for First Business Finl Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBIZ#NASDAQ">FBIZ</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $60.4, along with a high estimate of $63.00 and a low estimate of $58.00. This upward trend is evident, with the current average reflecting a 5.96% increase from the previous average price target of $57.00.
<img src="https://www.benzinga.com/files/images/story/2025/1745877656_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A comprehensive examination of how financial experts perceive First Business Finl Servs is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;-----------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Nathan Race &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $58.00&#x7C;$57.00 &#x7C; 
&#x7C;Damon Delmonte &#x7C;Keefe, Bruyette &amp; Woods&#x7C;Lowers &#x7C;Outperform &#x7C; $59.00&#x7C;$60.00 &#x7C; 
&#x7C;Nathan Race &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $63.00&#x7C;$58.00 &#x7C; 
&#x7C;Damon Delmonte &#x7C;Keefe, Bruyette &amp; Woods&#x7C;Raises &#x7C;Outperform &#x7C; $60.00&#x7C;$58.00 &#x7C; 
&#x7C;Daniel Tamayo &#x7C;Raymond James &#x7C;Raises &#x7C;Outperform &#x7C; $62.00&#x7C;$52.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to First Business Finl Servs. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of First Business Finl Servs compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for First Business Finl Servs's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of First Business Finl Servs's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FBIZ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on First Business Finl Servs analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About First Business Finl Servs</h2>
First Business Financial Services Inc operates as a bank holding company. The Bank operates as a business bank, delivering a full line of commercial banking products including commercial loans and commercial real estate loans, to meet the specific needs of small and medium-sized businesses, business owners, executives, professionals, and high-net-worth individuals. The company's products and services include commercial lending, SBA lending and servicing, asset-based lending, equipment financing, factoring, trust, and investment services, treasury management services, and a broad range of deposit products. Geographically all the business activity functioned through the region of the United States.
<h3>A Deep Dive into First Business Finl Servs's Financials</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: First Business Finl Servs displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 12.34%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: First Business Finl Servs's net margin excels beyond industry benchmarks, reaching 33.64%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): First Business Finl Servs's ROE excels beyond industry benchmarks, reaching 4.49%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): First Business Finl Servs's ROA excels beyond industry benchmarks, reaching 0.37%. This signifies efficient management of assets and strong financial health.
Debt Management: First Business Finl Servs's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.04, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FBIZ

A Glimpse Into The Expert Outlook On First Business Finl Servs Through 5 Analysts

In the preceding three months, 15 analysts have released ratings for Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">8</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Micron Technology and provided 12-month price targets. The average target is $124.73, accompanied by a high estimate of $200.00 and a low estimate of $84.00. Observing a downward trend, the current average is 7.41% lower than the prior average price target of $134.71. 
<img src="https://www.benzinga.com/files/images/story/2025/1745877641_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Micron Technology by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Timothy Arcuri &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $92.00&#x7C;$130.00 &#x7C; 
&#x7C;Tom O'Malley &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $95.00&#x7C;$115.00 &#x7C; 
&#x7C;Christopher Danely &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $110.00&#x7C;$120.00 &#x7C; 
&#x7C;Guohan Wang &#x7C;China Renaissance &#x7C;Announces &#x7C;Hold &#x7C; $84.00&#x7C;- &#x7C; 
&#x7C;Christopher Danely &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $120.00&#x7C;$150.00 &#x7C; 
&#x7C;Tom O'Malley &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $115.00&#x7C;$110.00 &#x7C; 
&#x7C;Joseph Moore &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Equal-Weight &#x7C; $112.00&#x7C;$91.00 &#x7C; 
&#x7C;Harlan Sur &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $135.00&#x7C;$145.00 &#x7C; 
&#x7C;Matt Bryson &#x7C;Wedbush &#x7C;Raises &#x7C;Outperform &#x7C; $130.00&#x7C;$125.00 &#x7C; 
&#x7C;Matthew Prisco &#x7C;Cantor Fitzgerald &#x7C;Maintains &#x7C;Overweight &#x7C; $130.00&#x7C;$130.00 &#x7C; 
&#x7C;Tristan Gerra &#x7C;Baird &#x7C;Raises &#x7C;Outperform &#x7C; $163.00&#x7C;$130.00 &#x7C; 
&#x7C;Kevin Cassidy &#x7C;Rosenblatt &#x7C;Lowers &#x7C;Buy &#x7C; $200.00&#x7C;$250.00 &#x7C; 
&#x7C;Timothy Arcuri &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $130.00&#x7C;$125.00 &#x7C; 
&#x7C;Matt Bryson &#x7C;Wedbush &#x7C;Maintains &#x7C;Outperform &#x7C; $125.00&#x7C;$125.00 &#x7C; 
&#x7C;Aaron Rakers &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $130.00&#x7C;$140.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Micron Technology. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Micron Technology compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Micron Technology's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Micron Technology's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MU/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Micron Technology analyst ratings.</a>
<h2>Get to Know Micron Technology Better</h2>
Micron is one of the largest semiconductor companies in the world, specializing in memory and storage chips. Its primary revenue stream comes from dynamic random access memory, or DRAM, and it also has minority exposure to not-and or NAND, flash chips. Micron serves a global customer base, selling chips into data centers, mobile phones, consumer electronics, and industrial and automotive applications. The firm is vertically integrated.
<h3>Micron Technology's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Micron Technology's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 38.27% as of 28 February, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 19.66%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Micron Technology's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 3.32%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 2.19%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Micron Technology's debt-to-equity ratio is below the industry average. With a ratio of 0.31, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 15 Analysts Discuss Micron Technology Stock

UBS analyst Dennis Geiger maintains Shake Shack (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) with a Neutral and lowers the price target from $140 to $100.

Price Target

SHAK

UBS Maintains Neutral on Shake Shack, Lowers Price Target to $100

Ratings for Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Alkermes and provided 12-month price targets. The average target is $40.5, accompanied by a high estimate of $52.00 and a low estimate of $32.00. This upward trend is apparent, with the current average reflecting a 5.19% increase from the previous average price target of $38.50.
<img src="https://www.benzinga.com/files/images/story/2025/1745877632_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Alkermes. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ashwani Verma &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $33.00&#x7C;$38.00 &#x7C; 
&#x7C;David Hoang &#x7C;Deutsche Bank &#x7C;Raises &#x7C;Buy &#x7C; $52.00&#x7C;$40.00 &#x7C; 
&#x7C;Leonid Timashev &#x7C;RBC Capital &#x7C;Announces &#x7C;Sector Perform &#x7C; $40.00&#x7C;- &#x7C; 
&#x7C;Chris Shibutani &#x7C;Goldman Sachs &#x7C;Raises &#x7C;Buy &#x7C; $32.00&#x7C;$30.00 &#x7C; 
&#x7C;Douglas Tsao &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Neutral &#x7C; $46.00&#x7C;$46.00 &#x7C; 
&#x7C;David Hoang &#x7C;Deutsche Bank &#x7C;Announces &#x7C;Buy &#x7C; $40.00&#x7C;- &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Alkermes. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Alkermes compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Alkermes's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Alkermes's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ALKS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Alkermes analyst ratings.</a>
<h2>Delving into Alkermes's Background</h2>
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
<h3>Alkermes: A Financial Overview</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Alkermes displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 13.91%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 34.07%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Alkermes's ROE stands out, surpassing industry averages. With an impressive ROE of 10.63%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Alkermes's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 6.96%, the company showcases efficient use of assets and strong financial health.
Debt Management: Alkermes's debt-to-equity ratio is below the industry average at 0.05, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALKS

Beyond The Numbers: 6 Analysts Discuss Alkermes Stock

Chubb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) has outperformed the market over the past 15 years by 1.13% on an annualized basis producing an average annual return of 11.98%. Currently, Chubb has a market capitalization of $112.68 billion. 
Buying $1000 In CB: If an investor had bought $1000 of CB stock 15 years ago, it would be worth $5,348.37 today based on a price of $281.18 for CB at the time of writing.
<h3>Chubb's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745877618_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

During the last three months, 4 analysts shared their evaluations of SLR Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRC#NASDAQ">SLRC</a>), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for SLR Inv, revealing an average target of $15.31, a high estimate of $17.25, and a low estimate of $12.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.23%. 
<img src="https://www.benzinga.com/files/images/story/2025/1745877619_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive SLR Inv. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;-----------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Finian O'Shea &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Underweight &#x7C; $12.00&#x7C;$13.00 &#x7C; 
&#x7C;Melissa Wedel &#x7C;JP Morgan &#x7C;Lowers &#x7C;Underweight &#x7C; $15.00&#x7C;$16.50 &#x7C; 
&#x7C;Casey Alexander &#x7C;Compass Point &#x7C;Raises &#x7C;Neutral &#x7C; $17.25&#x7C;$16.50 &#x7C; 
&#x7C;Ryan Lynch &#x7C;Keefe, Bruyette &amp; Woods&#x7C;Raises &#x7C;Market Perform &#x7C; $17.00&#x7C;$16.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to SLR Inv. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of SLR Inv compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for SLR Inv's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into SLR Inv's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SLRC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on SLR Inv analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know SLR Inv Better</h2>
SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. It invests majorly in leveraged middle-market companies in the form of senior secured loans, financing leases and to a lesser extent, unsecured loans and equity securities.
<h3>Financial Insights: SLR Inv</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: SLR Inv's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -5.69%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: SLR Inv's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 92.15%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): SLR Inv's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.28%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): SLR Inv's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.92%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.04.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SLRC

The Analyst Verdict: SLR Inv In The Eyes Of 4 Experts

In the current market session, Texas Roadhouse Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXRH#NASDAQ">TXRH</a>) share price is at $166.66, after a 3.11% increase. Moreover, over the past month, the stock fell by 1.34%, but in the past year, went up by 3.66%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1745877619_0_0.png" alt="Past Year Chart" />

<h3>How Does Texas Roadhouse P/E Compare to Other Companies?</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 90.23 in the Hotels, Restaurants &amp; Leisure industry, Texas Roadhouse Inc. has a lower P/E ratio of 24.98. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1745877619_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

TXRH

Price Over Earnings Overview: Texas Roadhouse

UBS analyst Lloyd Walmsley maintains Tripadvisor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIP#NASDAQ">TRIP</a>) with a Neutral and lowers the price target from $18 to $15.

TRIP

UBS Maintains Neutral on Tripadvisor, Lowers Price Target to $15

Farmers &amp; Merchants (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FMAO#NASDAQ">FMAO</a>) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.42 by 21.43 percent. This is a 30.77 percent increase over earnings of $0.39 per share from the same period last year.

Earnings

Earnings Beats

FMAO

Farmers & Merchants Q1 EPS $0.51 Beats $0.42 Estimate

Warren Buffett is considered a hero, mentor<a href="https://www.benzinga.com/general/education/24/08/40652464/warren-buffett-celebrates-94th-birthday-with-1-trillion-market-cap-milestone-a-look-back-at-hig"> and investing legend </a>to many people over the years. An autograph from the legendary investor is a coveted keepsake for many and some are up for sale soon.
What Happened: Continuing <a href="https://www.benzinga.com/25/04/44877870/warren-buffett-the-best-advice-giver-says-melinda-gates-heres-wisdom-she-uses-in-philanthropy">his philanthropic work</a>, Buffett is donating proceeds from a book to a homeless shelter in his hometown of Omaha, Nebraska.
The Stephen Center is receiving proceeds from "60 Years of Berkshire Hathaway," a book that celebrates the 60th anniversary of Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>), the conglomerate that Buffett famously runs.
The book includes photos, quotes and stories from Buffett and the late Berkshire vice chairman Charlie Munger, according to Observer.
Buffett previously highlighted the Stephen Center in his annual letter to shareholders this year. The nonprofit saw a boost in phone calls, website visitors and social media followers after Buffett's mention.
"Let's face it: this kind of opportunity, particularly from this kind of person, doesn't happen often," Stephen Center CEO Chris Knauf told Observer.
The nonprofit helps provide emergency shelter services, addiction recovery and affordable housing units, according to the report. You may not be a billionaire like Warren Buffett, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/trading-ideas/25/04/45029510/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-62">check out five stocks flying under the radar that deserve your attention.</a>
Book Sales and Autographs: According to the report, around 5,000 copies of the book are available to purchase at the annual Berkshire Hathaway shareholder meeting happening on May 2 and May 3.
There are 18 copies of the book signed by Buffett and former Berkshire employee and the book's curator Carrie Sova.
The autographed copies of the book are being offered exclusively to shareholders who donate $5,000 or more to the Stephen Center.
Buffett is matching all donations made by shareholders to the Stephen Center dollar-for-dollar.
Earlier this month, the first eight signed copies of the book were sold via auction on the nonprofit's website. Each of the copies sold for more than $5,000, with bids of $2,000 to $100,000. The auction of the first eight books raised $630,000 for the shelter when counting bids and Buffett's matched donations.
The remaining 10 signed copies of the book will be auctioned at the Stephen Center's booth at the Berkshire Hathaway shareholder meeting. Given the fact that there will be thousands of Buffett fans in attendance, the books could go for a higher amount than the first eight copies sold.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/management/25/02/43475330/warren-buffetts-1962-signed-stock-certificate-sells-at-auction-heres-what-it-fetched">Warren Buffett&#8217;s 1962 Signed Stock Certificate Sells At Auction: Here&#8217;s What It Fetched</a></li>
</ul>
Photo: Photo Agency / Shutterstock

Entertainment

Media

Warren Buffett Autographed Books To Help Charity: Here's How You Can Get Legendary Investor's Signature

UBS analyst Manav Gupta maintains Valero Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>) with a Buy and lowers the price target from $160 to $150.

UBS Maintains Buy on Valero Energy, Lowers Price Target to $150

UBS analyst Dennis Geiger maintains Wendy's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>) with a Neutral and lowers the price target from $16 to $14.

UBS Maintains Neutral on Wendy's, Lowers Price Target to $14

Waste Management Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) reported mixed first-quarter financial results after the bell on Monday, and shares are moving lower. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/04/b45054510/wm-announces-first-quarter-2025-earnings">of the report</a>.
<ul>
<li>Q1 Revenue: $6.02 billion, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $6.12 billion</li>
</ul>
<ul>
<li>Q1 Adjusted EPS: $1.67, versus estimates of $1.62</li>
</ul>
Total revenue was up 16.7% on a year-over-year basis. Waste Management said it generated $1.21 billion in cash from operations during the quarter, resulting in $475 million in free cash flow, in line with company expectations.
The company ended the first quarter with $216 million in cash and cash equivalents, down from $414 million at the end of the fourth quarter. 
&#8220;These solid&nbsp;first quarter&nbsp;results, as well as the strength and resiliency of our business model, give us confidence we are on pace to achieve our 2025&nbsp;outlook,&#8221; said&nbsp;Jim Fish, president and CEO of Waste Management.
Waste Management <a href="https://www.benzinga.com/pressreleases/25/01/b43324253/wm-announces-fourth-quarter-and-full-year-2024-earnings">previously guided</a> for full-year revenue of $25.5 billion to $25.8 billion. The company also forecasted for full-year free cash flow of approximately $2.68 billion to $2.78 billion when it reported fourth-quarter results.
Waste Management executives will further discuss the quarter on a conference call with investors and analysts at 10 a.m. ET Tuesday morning.
WM Price Action: <a href="http://benzinga.com/quote/WM">Waste Management shares</a> were down 1.78% at $225.01 after-hours at publication Monday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/management/25/04/45053723/nxp-semiconductors-reports-q1-earnings-very-uncertain-operating-environment-tied-to-tariffs-ceo-transition-shares-fall">NXP Semiconductors Reports Q1 Earnings: &#8216;Very Uncertain&#8217; Operating Environment Tied To Tariffs, CEO Transition, Shares Fall</a></li>
</ul>
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/45054717/transocean-stock-climbs-after-mixed-q1-results-eps-miss-revenue-beats">Transocean Stock Climbs After Mixed Q1 Results: EPS Miss, Revenue Beats</a></li>
</ul>
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/45053893/amkor-technology-shares-climb-after-q1-revenue-beats-q2-revenue-guidance-above-estimates">Amkor Technology Shares Climb After Q1 Revenue Beats, Q2 Revenue Guidance Above Estimates</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/paulmatthew">BCFC</a>/Shutterstock.

After-Hours Center

Movers

Waste Management Stock Dips On Mixed Q1 Results, Company Says It's 'On Pace' To Achieve 2025 Outlook

UBS analyst Dennis Geiger maintains Wingstop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) with a Neutral and lowers the price target from $300 to $255.

WING

UBS Maintains Neutral on Wingstop, Lowers Price Target to $255

Press Releases

CG Oncology Announces Proposed Public Offering

Financing

CG Oncology Announces Pricing of Public Offering

CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Health Care

CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference

CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates

CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

CGON

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Apogee Therapeutics

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

Beam Therapeutics

Biohaven

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Galapagos NV - American Depositary Shares

Galapagos

GRAIL

IDEAYA Biosciences

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Disc Medicine

Janux Therapeutics

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Mesoblast Limited - American Depositary Shares

Mesoblast

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

MannKind

Metsera

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co

ARS Pharmaceuticals

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Vericel

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Cantor Fitzgerald

HC Wainwright & Co.

Scotiabank

Morgan Stanley

Screenshot 2024-03-05 at 6.31.45 PM

Biotech

CADL

CLDI

TOVX

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

WIIM

CG Oncology shares are trading higher after the company announced that cretostimogene grenadenorepvec monotherapy data was presented at the American Urological Association Annual Meeting.

Comments

CG Oncology

Intérêt court

CG Oncology (NASDAQ:CGON) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL